Expired activity
Please go to the PowerPak homepage and select a course.

Evidence for Change: Optimizing Outcomes in Diabetic Retinopathy and Diabetic Macular Edema

A Conversations in CareTM CME/CE Supplement for Managed Health Care Executives

This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.
Postgraduate Institute for Medicine MedEdicus LLC

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Release date:

February 11, 2020

Expiration date:

February 11, 2021

Estimated time to complete the activity:

90 minutes


Dante J. Pieramici, MD (Chair)
California Retina Consultants
California Retina Research Foundation
Santa Barbara, California

Gary Owens, MD
Gary Owens Associates
Ocean View, Delaware

Ankoor R. Shah, MD
Retina Specialist
Retina Consultants of Houston
Assistant Professor of Clinical Ophthalmology
Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College
Houston, Texas

Winston Wong, PharmD
W-Squared Group
Longboat Key, Florida


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Gary Owens, MD
Fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speakers' bureaus) from Regeneron Pharmaceuticals, Inc

Dante J. Pieramici, MD
Consulting fees from Adverum; Allegro Ophthalmics, LLC; Gemini Therapeutics; Genentech, Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; and Regenxbio Inc

Contracted research from Adverum; Aerie Pharmaceuticals, Inc; Apellis Pharmaceuticals; Chengdu Kanghong Pharmaceutical Group Co Ltd; Gemini Therapeutics; Genentech, Inc; Ionis Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; and Stealth BioTherapeutics Inc

Ankoor R. Shah, MD
Consulting fees from Novartis Pharmaceuticals Corporation and Ocular Therapeutix, Inc

Winston Wong, PharmD
Consulting fees from AstraZeneca; Pfizer Inc; and Relypsa Inc

The PIM planners, managers, and reviewers have nothing to disclose. The MedEdicus planners, managers, and reviewers have nothing to disclose.


jointly accredited by (ACCME)In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008162-9999-20-1070-H01-P
Credits: 1.5 hours (0.15 CEUs)
Type of Activity:
Fee Information:
There is no fee for this educational activity.


This accredited activity has been designed for pharmacists.


During the period February 11, 2020, through February 11, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer, then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your Statement of Credit will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 3 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this activity is to foster better collaboration between payers and providers in the selection of the most optimal treatment regimens for patients with diabetic retinopathy (DR) and diabetic macular edema (DME).


Upon completion of this activity, participants should be better able to:

  • Compare anatomic and visual outcomes associated with various treatments for DR and DME
  • Evaluate evidence supporting individualized treatment strategies for patients with DR and DME
  • Apply evidence-based approaches to optimize value-based treatment selection for DR and DME
  • Provide accurate and appropriate counsel as part of the treatment team


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This CME/CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 183